Equity Field Notes from temporal sources

[DanWebzster]

PAVM is a medical device marketer with 3 commercially-available products.

* Esocheck is a 5-min non-invasive office-based procedure that is significantly cheaper than upper endoscopy. GERD sufferers are a burgeoning market for this product

* Esoguard is a confirmatory diagnostic for those who are determined to be at risk by Esocheck

* Carpx is minimally invasive device for treating Carpal Tunnel Syndrome.


These are pre-commercial prospects that may occur in 2021:

Esocure is Barrets Syndrome ablation devise that will be submitted for 510(k) approval. Submission is likely to occur in H-1 for prospective approval in H-2.

Port IO is an implantable intraosseus device for direct access to bone marrow. If covidiocy abates, clinical trials may once again progress. Or, maybe covidiocy is just an excuse for PAVM to manage over-extended resources.

PAVM may close on the sale of a disposable application of its Nextflo Gravitational Infusion System. The cash from such a sale is much needed.

PAVM is likely to submit for 510(k) clearance for the broadest applications of the Nextflo system that it can take to market.

This stock has many followers; but, they rarely mention fundamentals. PAVM burned 5.6M in Q2/20 with 14M cash and debt climbing beyond 12M. The share count has quadrupled since the beginning of 2018.